IFNG and neoplasm: Similarly, syndecan-1 (SDC1) restrained IFN-γ-STAT1 signaling and antigen presentation in tumor cells and thereby attenuated the sensitivity to T cell-mediated cytotoxicity and induced immunotherapy resistance [66].